![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Synairgen Doses First Patient in COVID-19 Trial
Synairgen Doses First Patient in COVID-19 Trial
![COVID-19 Clinical Trial](https://www.fdanews.com/ext/resources/test/Drug-Images4/COVID-19-CLINICAL-TRIAL.gif?t=1585696642&width=430)
U.K.-based Synairgen has begun a clinical trial of its antiviral SNG001 in COVID-19 patients at its initial trial site.
The company is conducting a phase 2 trial of the inhaled formulation of interferon-beta-1a. The pilot phase will include 100 COVID-19 patients.
In two phase 2 clinical trials of SNG001 in asthma patients, the drug activated antiviral pathways in the lung and improved lung function in patients with respiratory viral infections.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct